Pharmaust Ltd
ASX:PAA

Watchlist Manager
Pharmaust Ltd Logo
Pharmaust Ltd
ASX:PAA
Watchlist
Price: 0.165 AUD -8.33%
Market Cap: 81.2m AUD

Relative Value

PAA doesn't have a meaningful market cap.

The Relative Value of one PAA stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.165 AUD, Pharmaust Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PAA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

PAA Competitors Multiples
Pharmaust Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Pharmaust Ltd
ASX:PAA
81.2m AUD 93.7 -10.6 -12.3 -12.3
US
Eli Lilly and Co
NYSE:LLY
984.9B USD 16.6 53.5 35.9 38.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 5.8 -157.8 0.4 1.9
US
Johnson & Johnson
NYSE:JNJ
525.1B USD 5.7 20.9 17.1 22.1
CH
Roche Holding AG
SIX:ROG
275.5B CHF 4.5 29.3 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
209.7B GBP 0 0.3 0 0
CH
Novartis AG
SIX:NOVN
219.2B CHF 4.9 19.1 15.2 19.6
US
Merck & Co Inc
NYSE:MRK
272.2B USD 4.2 14.3 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.5 16.7 11.6 13.5
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.1B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
AU
Pharmaust Ltd
ASX:PAA
Average P/E: 21.1
Negative Multiple: -10.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -157.8 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
0.3
37%
0
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
16.7
3%
5.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Pharmaust Ltd
ASX:PAA
Average EV/EBITDA: 45.5
Negative Multiple: -12.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.9
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
0.4
36%
0
US
Johnson & Johnson
NYSE:JNJ
17.1
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
0
10%
0
CH
Novartis AG
SIX:NOVN
15.2
6%
2.5
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
1%
11.6
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Pharmaust Ltd
ASX:PAA
Average EV/EBIT: 99.7
Negative Multiple: -12.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
1.9
98%
0
US
Johnson & Johnson
NYSE:JNJ
22.1
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
0
23%
0
CH
Novartis AG
SIX:NOVN
19.6
12%
1.6
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5